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Antimicrobial susceptibility of Neisseria
gonorrhoeae isolates from symptomatic men
attending the Nanjing sexually transmitted
diseases clinic (2011–2012): genetic characteristics
of isolates with reduced sensitivity to ceftriaxone
Sai Li1, Xiao-Hong Su1*, Wen-Jing Le1, Fa-Xing Jiang2, Bao-Xi Wang1 and Peter A Rice3
Abstract
Background: Evolving gonococcal antimicrobial resistance (AMR) poses a serious threat to public health. The aim
of this study was to: update antimicrobial susceptibility data of Neisseria gonorrhoeae recently isolated in Nanjing,
China and identify specific deteminants of antimicrobial resistance and gentoypes of isolates with decreased
sensitivity to ceftriaxone.
Methods: 334 N. gonorrhoeae isolates were collected consecutively from symptomatic men attending the Nanjing
STD Clinic between April 2011 and December 2012. The minimum inhibitory concentrations (MICs) for penicillin,
tetracycline, ciprofloxacin, spectinomycin and ceftriaxone were determined by agar plate dilution for each isolate.
Penicillinase-producing N. gonorrhoeae (PPNG) and tetracycline-resistant N. gonorrhoeae (TRNG) were examined and
typed for β-lactamase and tetM encoding plasmids respectively. Isolates that displayed elevated MICs to ceftriaxone
(MIC ≥0.125 mg/L) were also tested for mutations in penA, mtrR, porB1b, ponA and pilQ genes and characterized
by Neisseria gonorrhoeae multi-antigen sequence typing (NG-MAST).
Results: 98.8% (330/334) of N. gonorrhoeae isolates were resistant to ciprofloxacin; 97.9% (327/334) to tetracycline
and 67.7% (226/334) to penicillin. All isolates were susceptible to ceftriaxone (MIC ≤0.25 mg/L) and spectinomycin
(MIC ≤32 mg/L). Plasmid mediated resistance was exhibited by 175/334 (52%) of isolates: 120/334 (36%) of isolates
were PPNG and 104/334 (31%) were TRNG. 90.0% (108/120) of PPNG isolates carried the Asia type β-lactamase
encoding plasmid and 96% (100/104) of TRNG isolates carried the Dutch type tetM containing plasmid. Elevated
MICs for ceftriaxone were present in 15 (4.5%) isolates; multiple mutations were found in penA, mtrR, porB1b and
ponA genes. The 15 isolates were distributed into diverse NG-MAST sequence types; four different non-mosaic penA
alleles were identified, including one new type.
Conclusions: N. gonorrhoeae isolates in Nanjing generally retained similar antimicrobial resistance patterns to
isolates obtained five years ago. Fluctuations in resistance plasmid profiles imply that genetic exchange among
gonococcal strains is ongoing and is frequent. Ceftriaxone and spectinomycin remain treatments of choice of
gonorrhea in Nanjing, however, decreased susceptibility to ceftriaxone and rising MICs for spectinomycin of
N. gonorrhoeae isolates underscore the importance of maintaining surveillance for AMR (both phenotypic and
genotypic).
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Background
Gonorrhea is the fifth most commonly reported infectious
disease in China; nearly 100,000 cases were reported offi-
cially nationwide in 2013 [1]. Worldwide, over 106 million
new infections are diagnosed annually [2]. Effective treat-
ment is key in preventing complications and controlling
transmission of N. gonorrhoeae. Unfortunately, this bac-
terium has developed resistance to antimicrobials (AMR)
including sulfonamides, penicillins, tetracyclines and quin-
olones [3,4]. In recent years treatment failures have oc-
curred when extended-spectrum cephalosporins (ESCs),
the most widely used agents for treatment of gonorrhea,
were used, and associated increases in AMR to ESCs have
been reported in several countries [5-11]. The molecular
mechanisms associated with reduced susceptibility or re-
sistance to ESCs include mutations in several gene loci;
penA [12-16], mtrR [17,18], penB [17,19], ponA [6,20] and
pilQ [21,22] and their multifaceted interactions [6,23].
Several public health organizations have published their
action/response plans to control the spread and impact of
ESCs-resistant gonococci [2,24,25]. These have stressed
the importance of enhancing quality-assured surveillance
of gonococcal AMR both locally and internationally, with
a focus on ESCs.
In China, the surveillance of N. gonorrhoeae AMR is
conducted by the National Center for Sexually Transmitted
Diseases (STDs) Control, China CDC, which systematically
collects N. gonorrhoeae AMR data from 10 ~ 16 geograph-
ically separate monitoring sentinels and provides external
quality assessment. Annual AMR rates are available in brief
reports issued by China CDC (1987-current) [26] and are
also published by the World Health Organization (WHO),
Western Pacific Region Gonococcal Antimicrobial Surveil-
lance Programme (1992–current) [27-29].
During 2011–2012, the period of this investigation,
ceftriaxone and spectinomycin were the only antimicro-
bial agents recommended officially in the Chinese guide-
lines for the treatment of gonorrhea [30], however, a
wide variety of antimicrobials including (fluoro) quino-
lones were prescribed unofficially outside of STD Clinics
and purchased over the counter to treat gonorrhea.
The Nanjing STD clinic, operating as a sentinel site in
Eastern China, performs AMR tests routinely on 10%–20%
of gonococcal isolates recovered in this city. We performed
this study in 2011–12, to assess the impact, in Nanjing, of
recent changes in ceftriaxone susceptibility of N. gonor-
rhoeae that have been reported [31-34] and to characterize
genetic determinants and NG-MAST sequence types (STs)
of isolates with decreased sensitivity to ceftriaxone.
Methods
Subjects and bacterial strains
N. gonorrhoeae isolates were isolated from male adults
with symptoms/signs of urethritis (confirmed by ≥5
polymorphonuclear neutrophils [PMNs]/oil immersion mi-
croscopic field seen in all urethral specimens) in the STD
clinic of the National Center for STD Control in Nanjing,
China between April 2011 and December 2012. These iso-
lates represented 18.1% of the reported gonorrhea cases in
Nanjing during this period. Epidemiological data was ac-
quired by interviews conducted by clinical staff using stan-
dardized data recording instruments. Isolates from all but
2 men were from ethnic Han (332/334) and 99.4% (332/
334) of men were heterosexual. The mean (± SEM) age
was 36.7 ± 3.3 years, the median, 36 (range: 19 to 65),
there being no significant difference (p > 0.05) compared
with the national average age of gonorrhea cases in men
(mean [± SEM], 34.9 ± 3.2). 61.3% of men were married.
Approval to enroll human subjects was given by the Insti-
tutional Review Board of the Institute of Dermatology,
Chinese Academy of Medical Science. The study was in-
troduced and explained to potential subjects who volun-
tarily gave written and signed consent. Urethral specimens
were collected with cotton swabs and immediately
streaked onto Thayer-Martin (T-M) selective medium. In-
oculated plates were incubated at 36°C in candle jars for
24–48 h. N. gonorrhoeae was identified by colonial morph-
ology, Gram’s stain, and oxidase testing, which are suffi-
cient to identify N. gonorrhoeae colonies isolated on
selective medium, particularly for samples from the ureth-
ral tracts of symptomatic men [35,36]. Isolates were
subcultured onto GC agar base (Difco, Detroit, MI) sup-
plemented with 1% IsovitaleX™(Oxoid, USA) and pure cul-
tures swabbed, suspended in tryptone-based soy broth and
frozen (−70°C) until used for antimicrobial testing.
Antimicrobial susceptibility testing
The minimum inhibitory concentrations (MICs; mg/L)
of N. gonorrhoeae to penicillin, tetracycline, ciprofloxa-
cin, spectinomycin and ceftriaxone were determined by
the agar dilution method (Clinical Laboratory Standards
Institute [37]), using 2-fold serial dilutions of antibiotics
(all purchased from Sigma Aldrich, Saint Louis, MO,
USA): penicillin 0.125–8 mg/L, tetracycline 0.25–16 mg/L,
ciprofloxacin 0.25–8 mg/L, spectinomycin 4–128 mg/L
and ceftriaxone 0.004–0.5 mg/L. WHO reference strains
A, G, I and J (kindly provided by Dr. J. W. Tapsall, Prince
of Wales Hospital, Sydney, Australia) and a ceftriaxone-
resistant strain (kindly provided by Carmen Ardanuy,
L’Hospitalet de Llobregat, Barcelona, Spain [38]) were
used as controls. In addition, we included, as controls, two
strains isolated from our prior study that had diminished
susceptibiltiy to ceftriaxone (MIC = 0.125 and 0.25 mg/L)
[39]. MIC breakpoints for assigning susceptibility, inter-
mediate and resistance status to N. gonorrhoeae isolates
were determined according to Clinical and Laboratory
Standards Institute (CLSI) Document M07-A9 (M100-
S22) [37].
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Production of β-lactamase was identified by paper
acidometric test (phenotype method) [39,40]. Resistance
patterns were defined as follows [41]:
 PPNG (Penicillinase-producing N. gonorrhoeae),
β-lactamase positive
 TRNG (Plasmid-mediated tetracycline-resistant
N. gonorrhoeae), MIC to tetracycline ≥16 mg/L, also
confirmed by PCR-based genotyping
 PPNG/TRNG, β-lactamase positive and MIC to
tetracycline ≥16 mg/L
 PenR (chromosomally mediated resistance to
penicillin), non-PPNG, non-TRNG, MIC to
penicillin ≥2 mg/L and MIC to tetracycline <2 mg/L
 TetR (chromosomally mediated resistance to
tetracycline), non-PPNG, non-TRNG, MIC to
tetracycline ≥2 mg/L and MIC to penicillin <2 mg/L
 CMRNG (chromosomal resistance to penicillin and
tetracycline), non-PPNG, non-TRNG, MIC to
penicillin ≥2 mg/L and MIC to tetracycline ≥2 mg/L.
Identification and typing of tetM and β -lactamase gene
producing plasmids
Bacterial DNA was extracted according to a published
method [39].
For tetM gene containing plasmids, PCR reactions were
performed using a universal forward primer; 5′ 825CTCG
AACAAGAGGAAAGC842 and reverse primers 5′1602GC
ATTCCACTTCCCAAC1586 to identify the presence of
the “American” type tetM plasmid and 5′ 1267TGCAGC
AGAGGGAGG1253 to identify the “Dutch” type. PCR
products were separated by agarose electrophoresis,
stained with ethidium bromide and visualized using ultra-
violet fluorescent light for the presence of a 778 bp frag-
ment (“American”) or a 443 bp fragment (“Dutch”) [42].
An American type tetM containing strain identified in our
previously study [39] and WHO reference strain G (Dutch
type) were used as positive controls.
β-lactamase producing plasmids were characterized
using multiplex PCR (employing specific forward and re-
verse primers [43]) followed by elecrophoresis to identify
specifically sized PCR products, thereby differentiating
three common plasmids: Asian (958 bp), African (1191 bp)
and Toronto (650 bp). Positive control PCR products de-
rived from plasmids pJD4 (Asian type), pJD5 (African
type) and pJD7 (Toronto type) (provided by J.R. Dillon,
University of Saskatchewan, Canada) were included in
each assay.
Sequencing of N. gonorrhoeae genetic determinants
associated with decreased susceptibility to ceftriaxone
Amplification of penA, mtrR, porB (and also ponA and
pilQ) was performed using published primers and con-
ditions [44,45]. PCR products were sequenced twice
bidirectionally on an Applied Biosystems 3730XL DNA
automatic sequencer. Nucleotide and deduced amino
acid sequences were edited and aligned against their re-
spective prototypes [44]. A newly identified PBP2 type
was designated XLI according to previously used no-
menclature [12,15,46-49].
Molecular epidemiological typing
N. gonorrhoeaemultiantigen sequence typing (NG-MAST)
was performed by PCR amplification and sequencing of
two high polymorphic fragments in porB and tbpB genes
according to previously described methods [50]. Allele
numbers and sequence type numbers were assigned
through the NG-MAST database (http://www.ng-mast.net).
Nucleotide sequence accession numbers
porB sequences were submitted to the GenBank nucleotide
database under accession numbers [Genbank: KF660589-
KF660594] and [Genbank: KF668353- KF668360]. Novel
penA nucleotide sequences associated with reduced sus-
ceptibility to ESCs identified in this study were deposited
in the GenBank database under accession number
[Genbank: KF576657].
Statistical analysis
The Chi-Square test (2-tailed) was used to assess sig-
nificance of associations and compare resistance rates;
p values <0.05 were considered significant. Statistical
analyses were performed using IBM SPSS Statistics ver-
sion 22.0.
Results
Antimicrobial susceptibilities
Among 652 consecutively enrolled male subjects with
urethritis, 340 (52.1%) were infected with N. gonor-
rhoeae; antimicrobial susceptibility testing of 334 suc-
cessfully retrieved isolatesis is summarized in Table 1
(six isolates were not recovered from storage or could
not be separated from contaminants). Resistance rates to
antibiotics formerly or now recommended for treatment
of gonorrhea in China were: ciprofloxacin 98.8%, tetra-
cycline 97.9%, penicillin 67.7%, all isolates were suscep-
tible to spectinomycin and ceftriaxone. The minimum
inhibitory concentration of 50% and 90% of gonococcal
isolates (MIC50/MIC90) for ciprofloxacin, tetracycline,
penicillin, spectinomycin and ceftriaxone were >8/>8,
8/>16, 2/>8, 16/32 and 0.03/0.06 mg/L, respectively.
Penicillin and tetracycline resistance phenotypes
Penicillin and tetracycline resistance phenotypes were
categorized based on plasmid or chromosomally medi-
ated resistance mechanisms. Overall, plasmid mediated
resistance to either penicillin or tetracycline was exhib-
ited by 175/334 (52%): 71/334 (21%) of isolates were
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PPNG exclusively; 55/334 (16%) were TRNG exclusively
and 49 (15%) were PPNG/TRNG. CMRNG or TetR alone
was identified in 27.8% and 18.3% of isolates, respectively.
PenR alone was not detected.
Molecular typing of PPNG and TRNG
120 β-lactamase producing N. gonorrhoeae isolates were
distributed into two plasmid types: Asian and African.
No Toronto plasmid was detected. 108 (90%) isolates
contained the Asian plasmid and 12 (10%) harbored the
African plasmid.
Among 104 isolates with the tetM determinant, 96.2%
(100/104) carried the Dutch type; the remaining 4 car-
ried the American-type.
The β-lactamase plasmid was present more frequently
in TRNG isolates than in non-TRNG isolates (47.1%
[49/104] vs. 30.9% [71/230]; p < 0.01; Table 2). Forty nine
PPNG/TRNG isolates exhibited two patterns that com-
bined β-lactamase and tetM containing plasmids: Asian
type β-lactamase expressing isolates always harbored the
Dutch tetM type; the combination of African type β-
lactamase and American type tetM was rarely identified
in PPNG/TRNG (3 isolates) in Nanjing (Table 2).
Genetic characteristics of N. gonorrhoeae isolates with
increased MIC to ceftriaxone
Fifteen (4.5%) isolates had elevated MICs (≥0.125 mg/L)
to ceftriaxone. A second determination on the 15 iso-
lates confirmed the MICs. According to recent CLSI
breakpoint criteria [37], these isolates would be classified
as “susceptible” but treatment failures have occurred
when infected strains possessed MICs around 0.125 mg/
L [6,10,11]. We examined these 15 isolates for genetic
mutations in penA, mtrR, penB, ponA and pilQ genes
(Table 3).
Four PBP2 amino acid sequence patterns were identi-
fied; PBP2 allele XVIII was the predominant type (n = 11),
followed by XIII (n = 2) and XII (n = 1). A new pattern
containing five mutations (345D insertion, A501V, F504L,
A510V and A516G) was designated PBP2 allele XLI, ac-
cording to the previously used nomenclature of PBP2 al-
leles in N. gonorrhoeae [12,15,46-49]; none of these is a
mosaic allele. However, 12 isolates (allele XVIII and XLI)
possessed an A501T substitution in PBP2, and 2 isolates
(allele XIII) had an A501V substitution.
Fourteen of fifteen isolates contained a single nucleotide
(A) deletion in the 13 bp inverted repeat motif located be-
tween −10 and −35 sequence in the mtrR promoter. Five
isolates (including two with ceftriaxone MICs = 0.25 mg/L)
also had a G45D or A39T substitution in the DNA-
binding motif of MtrR, and one isolate possessed a single
amino acid replacement (A39T). We did not identify the
recently described C-to-T mutation 120 bp upstream of
the mtrC start codon, termed mtr120 [51].
All isolates possessed penB resistance determinants with
substitutions at both G120 and A121 in loop 3 of the
PorB1b outer membrane porin; these included G120K/
A121D (n = 7), G120K/A121G (n= 6), G120N/A121D (n = 1)
and G120K/A121N (n = 1).
Finally, the L421P substitution in PBP1 caused by a
single nucleotide mutation (T to C) in the ponA gene
was detected in all isolates; we saw no alternations in
the pilQ gene.
The fifteen isolates that harbored 14 different porB se-
quences and 12 tbpB sequences were assigned to 15 differ-
ent NG-MAST STs: ST8737, ST3289, ST2186, ST3746,
ST2461, ST5061 and 9 new STs. Eleven isolates with the
PBP2 allele, XVIII, the most common PBP2, were resolved
into 11 separate NG-MAST STs (Table 3).
Discussion
Our study reported high-levels of resistance to previously
recommended therapeutic agents for N. gonorrhoeae of
Table 1 In vitro antimicrobial susceptibility of Neisseria gonorrhoeae: clinical isolates (n = 334)
Antimicrobial breakpoints
(susceptible/resistant [mg/L])a
No. (%) MIC (mg/L)
Susceptible Intermediate Resistant Range MIC50 MIC90
Penicillin G (S ≤ 0.06/R≥ 2) 0 108 (32.3) 226 (67.7) 0.125 to >8 2 >8
Tetracycline (S ≤ 0.25/R≥ 2) 2 (0.6) 5 (1.5) 327 (97.9) 0.25 to >16 8 >16
Ciprofloxacin (S ≤ 0.06/R≥ 1) 0 4 (1.2) 330 (98.8) ≤0.25 to >8 >8 >8
Spectinomycin (S ≤ 32/R ≥ 128) 334 (100) 0 0 ≤4 to 32 16 32
Ceftriaxone (S ≤ 0.25) 334 (100) - - 0.004 to 0.25 0.03 0.06
aAntimicrobial breakpoints that distinguish susceptible from resistant gonococcal isolates (CLSI Document M07-A9 (M100-S22) [35]. MIC: minimum inhibitory
concentration.
Table 2 Distribution of β-lactamase-encoding and
tetM-encoding plasmids: Neisseria gonorrhoeae clinical
isolates (n = 334)
Type of
tetM -encoding
plasmid
Type of β-lactamase producing
plasmid
Asian/New Zealand African/Nîmes β-lactamase
negative
Dutch 46 0 54
American 0 3 1
tetM negative 62 9 159
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isolates from men with urethritis in Nanjing (2011–12):
ciprofloxacin (98.8%); tetracycline (97.9%) and penicillin
(67.7%). Rates of resistance have remained unchanged
compared with that of 2006, the last year of a six yearly se-
quential measurement [39]. Similar patterns of resistance
have also been noted from other cities in southern China;
Shanghai (ciprofloxacin 98.7%, tetracycline 73.6%, penicil-
lin 98.1% [exact time period for isolates collection not
available]) [52], Shenzhen (ciprofloxacin 96.1%, tetra-
cycline 99.0% in 2008–2012) [53], Hainan (ciprofloxacin
98.0% in 2011) [54] and other western pacific and south-
eastern Asian regions including Vietnam, Korea, India,
Pakistan and Bhutan [28,31,55-57]. The contribution of
plasmid mediated resistance was similar in Nanjing in the
period 2011–12 compared to 2006 [39], but during this
interval declines in the proportion of PPNG have been ob-
served in Korea [57], Canada [58], Latin America and the
Caribbean countries [59]. Because treatment of gonorrhea
with ciprofloxacin, tetracycline and penicillin has long
been discontinued in Nanjing [30,39], persistence of re-
sistant phenotypes may be explained by the stability of
mechanisms that promote resistance or the presence of
unidentified selection pressures due to use of antibiotics
for other reasons including the common practice of self-
medication with antibiotics. In our study, 33% of men with
gonococcal urethritis reported self-administration of anti-
biotics in the 30 days prior to their clinic visit (unpub-
lished data).
It is encouraging to note that the percentage of gono-
cocci isolates with decreased susceptibility to ceftriaxone
(MIC ≥0.125 mg/L) declined significantly from 9.1% (18/
198) in 2006 [39] to 4.5% (15/334) in 2011–12 (p = 0.04);
a one dilution decrease of the modal MIC for ceftriax-
one was also observed (0.06 mg/L in 2006 to 0.03 mg/L
in 2011–12) (Figure 1). In Europe [32,60-63], Australia [64],
Africa [65-67], the western hemisphere [33,58,59,68-70]
and the South-East Asia Region [31], MICs to ceftriaxone
have risen during this period. Nonetheless, it is of concern
that the distribution of spectinomycin MICs shifted up-
ward in Nanjing during the same interval, between 2006
and 2011–12 (Figure 2) [39]. In 2006, an MIC = 32 mg/L
to spectinomycin was observed in 1.0% of strains, rising to
18.3% in 2011–12 (p < 0.01), coinciding with a significant
decrease in the percentage of strains whose MICs ≤8 mg/L
(p < 0.01). Opposing trends in resistance of gonococcal
isolates to ceftriaxone and spectinomycin may, in part, re-
sult from the greater use of spectinomycin in the Nanjing
STD clinic. Ninety-eight percent of gonococcal urethritis
cases in men were prescribed spectinomycin as recently as
in 2012, in large part because of the lower price of
Chinese-manufactured spectinomycin vs. imported ceftri-
axone and the requirements for cefriaxone skin testing
prior to administration. Resistance of N. gonorrhoeae to
spectinomycin, although rarely reported [31,33,65,71], be-
cause of limited access to and use of this antibiotic in
many countries outside of China, may be the “cautionary
Table 3 Genetic characteristics of Neisseria gonorrhoeae with increased MICs (n = 15) to ceftriaxone (≥0.125 mg/L)
Isolate
no.
Ceftriaxone
MICs (mg/L)
Antimicrobial
characteristics
NG-MAST PBP2
allele
Polymorphisms in:
porB tbpB STs MtrR PorB1b PBP1 PilQ
NJ-1 0.25 CMRNG, CipR# 5658 111 9530* XVIII −57A del, A39T G120K, A121D L421P wt
NJ-2 0.25 CMRNG, CipR 5175 328 8737 XVIII −57A del, A39T G120K, A121D L421P wt
NJ-3 0.125 PPNG, CipR 5659 107 9531* XVIII −57A del G120K, A121G L421P wt
NJ-4 0.125 PP/TRNG, CipR 1053 186 3289 XVIII −57A del G120K, A121D L421P wt
NJ-5 0.125 PPNG, CipR 1854 33 9532* XLI** −57A del G120N, A121D L421P wt
NJ-6 0.125 PP/TRNG, CipR 543 294 9533* XVIII A39T G120K, A121G L421P wt
NJ-7 0.125 CMRNG, CipR 5660 186 9534* XVIII −57A del G120K, A121G L421P wt
NJ-8 0.125 CMRNG, CipR 505 135 2186 XVIII −57A del G120K, A121D L421P wt
NJ-9 0.125 CMRNG, CipR 1285 4 9535* XIII −57A del, G45D G120K, A121D L421P wt
NJ-10 0.125 TRNG, CipR 4 831 3746 XIII −57A del G120K, A121D L421P wt
NJ-11 0.125 CMRNG, CipR 3530 4 9536* XVIII −57A del G120K, A121G L421P wt
NJ-12 0.125 CMRNG, CipR 1198 156 2461 XVIII −57A del, A39T G120K, A121G L421P wt
NJ-13 0.125 CMRNG, CipR 5661 4 5061 XVIII −57A del, G45D G120K, A121N L421P wt
NJ-14 0.125 CMRNG, CipR 2978 1058 9537* XII −57A del G120K, A121D L421P wt
NJ-15 0.125 TRNG, CipR 543 438 9538* XVIII −57A del G120K, A121G L421P wt
wt, wild type.
*New NG-MAST STs detected in this study.
**A new PBP2 allele previously not identified was named XLI according to previously used Nomenclature.
#isolates exhibiting resistance to ciprofloxacin (MIC ≥ 1 mg/L).
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tale” of clinical failure when it is used as primary treatment
of gonorrhea [72].
Plasmids carried by PPNG and TRNG isolates have
changed over time in Nanjing [39]. The highly active
TEM β-lactamase gene is carried by a family of plasmids
in N. gonorrhoeae. Since 1976, at least eight different plas-
mids have been identified from geographically distinct lo-
cations [73]. The β-lactamase gene has been found on
Asian-, African- and Toronto - type plasmids carried by
epidemic strains of N. gonorrhoeae [74], even while new
types such as the Johannesburg and Australian plasmids
are being discovered [75,76]. We did not differentiate the
Nîmes plasmid from the African-type or the New Zealand
plasmid from the Asian-type, owing to the identical sizes
of the PCR products but we would have identified the
novel Johannesburg plasmid identified by the 458 bp PCR
products using the primer pair designed for the African-
type plasmid. Using a simple multiplex PCR method [43],
we detected either Asian/ New Zealand type (n = 108) or
African/Nîmes type (n = 12) plasmids in all penicillinase-
positive isolates. The Asian/New Zealand type plasmid
dominated, while the newly emerging African/Nimes type,
which was absent in Nanjing isolates of 2006, and were
epidemic in the United Kingdom (UK) and West Africa
Figure 1 Distribution of ceftriaxone MICs of Neisseria gonorrhoeae isolates: Nanjing, 2006 (n = 198) and 2011–12 (n = 334).
Figure 2 Distribution of spectinomycin MICs of Neisseria gonorrhoeae isolates: Nanjing, 2006 (n = 198) and 2011–12 (n = 334).
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[74], may have reflected movement of N. gonorrhoeae
across continents. In like manner, while the Dutch vari-
ant (n = 100) of tetM still predominates, identification of
the minor American variant (n = 4) in Nanjing is just
beginning.
Decreased susceptibility to ceftriaxone was demon-
strated in 15 (4.5%) of the Nanjing isolates of N. gonor-
rhoeae (cefixime was not tested/not used in Nanjing).
Differing from gonococcal isolates that were resistant
or less susceptible to ESCs from Japan [77], Europe
[10,38,78-80], North America [47,81] or South Africa
[67], the mosaic-like structure that is usually located in
the region of the transpeptidase-encoding domain of
penA of resistant gonococcal strains, was not identified
in the Nanjing isolates. Similar to strains recently
tested from Southeast Asia (Vietnam) [56] and South
Asia [55], the majority of our 15 isolates with de-
creased susceptibility contained mutations in PBP2 at
position 501: A501V or A501T. Whiley et al. [13] have
suggested that gonococcal-specific A501 substitutions
may contribute more significantly to reduced ceftriax-
one susceptibility than mosaic sequences. Three A501
mutation-containing patterns of PBP2 (XVIII, XIII and
XLI) in our study have been reported to be epidemiologi-
cally connected with increased MICs to ceftriaxone
[15,44,45]. The results of a modeling study indicated that
reduced susceptibility to cephems such as cefixime and
ceftriaxone is due to a conformational alteration of the
beta-lactam-binding pocket caused by an A501 mutation
in non-mosaic strains [13]. Results of the model have been
confirmed by isogenic transformation demonstrating, that
an A501V(T) mutation in PBP2 results in increased MIC
to ceftriaxone in a non-mosaic penA containing strain
[82]. Polymorphisms in mtrR and penB genes (and also
ponA) were also evident in our isolates.
Azithromycin, combined with ceftriaxone, recently has
been recommended by the United States [83] and the
United Kingdom [84] and is now also in the European
guidelines [85] for the treatment uncomplicated gonorrhea.
This combination had not been recommended for the
treatment of gonorrhea in China during the study period
(2011–2012). Azithromycin resistance of N. gonorhoeae
isolates from the Nanjing STD clinic was 6.8% [86] in 2008
and 2009, which exceeded the 5% threshold suggested by
WHO for emperic use as a first line agent [26-29].
Our study has several limitations. Gonococcal isolates
were collected only from men with symptomatic ureth-
ritis. 33% of infected men had used antibiotics prior to
their clinic visit, which may have contributed to in-
creased resistance of their gonococcal isolates. Exclusion
of isolates from asymptomatic men and from extragential
sites (there were only two MSMs in our study) may have
underestimated AMR [87-89]. Simultaneously, infected
men may have been cured of infection with isolates
sensitive to the antibiotics that they had used earlier and
therefore not seen in the clinic. This may have also led to
an overabundance of more resistant N. gonorrhoeae.
Conclusions
This study confirmed that ceftriaxone and spectino-
mycin remain effective empiric first-line therapy for gon-
orrhea in Nanjing. However, years of discontinued use of
formerly recommended antimicrobial agents did not
restore the sensitivities of gonococcal strains to cipro-
floxacin, penicillin or tetracycline. Changes and multiple
representative types of resistance plasmid profiles high-
light frequent influx and exchange of N. gonorrhoeae
strains. Reduced ceftriaxone susceptibility was found in
4.5% of gonococcal isolates and alterations in penA,
mtrR, and penB genes were important determinants of
resistance. Sustained surveillance of gonococcal pheno-
typic and genotypic AMR is an important element in the
control of gonoccocal infection.
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